ADHD in the Arab World: The Data, Country by Country

One Region, No Single Number

Over the past month, this blog has published four separate data reports: ADHD in Egypt, ADHD in Saudi Arabia, ADHD in the UAE, and ADHD in the Gulf. Read on their own, each is a country's honest accounting of what its researchers have actually measured. Read together, something else becomes visible — a shape that no single country report can show, because it only appears when you step back far enough to see all four studies sitting next to each other.

There is no single number for ADHD in the Arab world — there are a dozen regional studies, four different medication systems, and one shared blind spot: a region that has barely begun to count a condition it still often reads as a character flaw. That is not a gap in this article's research. It is the finding. Every major health publisher that writes about ADHD writes about it as a Western condition with Western numbers, because that is where the large, well-funded studies exist. This region has never gotten the same treatment — not because ADHD is rarer here, but because almost nobody has counted it with the same rigor, or for long enough, to produce a number the way the West has.

This piece will not manufacture the number that's missing. What it will do is put the four spokes side by side, name the pattern that runs underneath all of them, and route you to whichever country's full report you need — because the counting has barely begun, and the honest starting point for anyone reading this from Cairo, Riyadh, Dubai, Kuwait City, Doha, Manama, or Muscat is to know exactly what has and hasn't been measured where they live.

What the Data Does and Doesn't Say

Start with what the data across the four countries actually does say, because it is not nothing. Egypt has three regional rating-scale and clinical studies, in three different governorates, all published in the last decade. Saudi Arabia has a formal 2023 meta-analysis pooling fourteen studies and hundreds of thousands of participants, on top of a national ADHD society and a Ministry of Health clinical protocol. The UAE has a national cross-sectional screening study of young adults, plus two older childhood studies. The Gulf states beyond Saudi have a scattering of smaller studies, anchored by one solid Omani figure. None of that is silence. Each country has produced at least some real, published evidence that ADHD exists in its population at rates broadly in line with the rest of the world.

Now the part that matters more: what none of it adds up to. It does not add up to a single, comparable regional prevalence rate — because the four countries measured different age groups (mostly children in Egypt and the Gulf, young adults in the UAE), used different instruments (DSM-5 rating scales in Fayoum, clinical confirmation in Menoufia, a validated self-report screen in the UAE, a systematic meta-analysis in Saudi Arabia), and asked different questions entirely (how many children show symptoms on a scale, versus how many young adults screen positive, versus a pooled estimate across dozens of unrelated studies). Stacking those four kinds of number into one regional figure would not average out the noise — it would manufacture a precision none of the underlying studies were built to support.

You cannot plan care for a number no one has measured — and across the Arab world, the measuring has only just begun. That is the floor this entire hub stands on. It is not a criticism of any single country; Saudi Arabia in particular has done more systematic work than most of its neighbors. It is a description of a region-wide starting point: strong studies exist in patches, adult data is almost nowhere, and the gaps between what's known and what isn't are themselves the most important fact in the room.

The Pattern Underneath All Four Countries

If the four numbers don't combine into one figure, what do they combine into? A pattern — the same one, showing up with local variation in every country this hub has covered. Three threads run through all four reports.

First, adults are almost never counted. Every country's strongest data is about children. Egypt's three studies are all school-age samples. The Gulf's clearest figure, Oman's 8.8%, is a childhood study. Saudi Arabia's meta-analysis pools mostly pediatric and mixed samples. The one country with a real adult figure — the UAE's 34.7% — immediately reveals why adult data is so rare: even where someone finally measured it, the number that came back was a screening result, not a diagnosis, because the diagnostic system built for children was never extended to catch the adults behind it.

Second, screening and diagnosis are two different things, and the region conflates them constantly. The UAE's national study is the clearest example: roughly a third of young adults screened positive for probable ADHD on a validated questionnaire, and almost none of them were ever formally diagnosed. That is not evidence that a third of a country's young adults have ADHD — it is evidence that the region has, in places, built the capacity to notice a problem without building the capacity to confirm or treat it.

Third, and underneath both of the above, is stigma. Every one of the four spokes describes some version of the same cultural reflex: a child who can't sit still or forgets instructions is read as lazy or badly raised rather than as a child with a neurodevelopmental condition, and an adult who suspects ADHD is often told, flatly, that it's something children have and adults grow out of. That reflex doesn't just delay individual diagnoses — it shapes which children ever reach a clinic in the first place, which is part of why the child-heavy data this region does have is itself likely an undercount.

Country by Country

Each of the four countries below has its own full report — the actual studies, the recognition gap specific to that country, the medication reality, and where to get help locally. What follows is the compressed shape of each; the depth is one click away.

Notice what the four cards have in common, beyond the region: no two of them are answering the same question. Egypt's spread is about method disagreement within one country. Saudi Arabia's confidence interval is enormous because fourteen studies didn't agree with each other. The UAE's number describes screening, not diagnosis. The Gulf's number exists for one country out of four and is silent for the rest. Four countries, four different kinds of "we don't fully know yet" — which is exactly why no one has counted yet a single Arab-world figure that would mean anything.

The Medication Reality, Region-Wide

Across all four countries, the regulatory shape is the same even where the specifics differ. ADHD stimulants are controlled substances everywhere in this region, not something available over the counter or freely brought across a border. Methylphenidate — the active ingredient in Ritalin and Concerta — is internationally classified as a Schedule II controlled substance, and every jurisdiction covered in this hub regulates it inside its own national narcotics-and-psychotropics framework (BMC Medicine, 2023). It is neither freely available nor freely importable anywhere here.

What varies by country is the finer grain: which specific stimulants are registered for use, how a prescription actually moves through the system, and how long the wait for a specialist runs. In Egypt, for instance, atomoxetine — a non-stimulant option — appears in the clinical literature as an alternative where stimulant access is constrained (Hamouda, 2025). Other countries in this hub have their own specific rules on what's registered and what isn't, and those specifics are worth reading in the relevant country spoke rather than flattening into a regional average here.

Two things hold no matter which of the four countries you're reading this from. Controlled everywhere, availability varies — the fact of control is regional, the details are national, and this article will not tell you how to source, import, or work around any of it. And whether medication is appropriate, which one, and at what dose is a decision for a licensed clinician working inside your own country's system — never something to arrange on your own. For the country-specific detail on what's registered and what a real prescription pathway looks like, the four spoke articles above go further than a regional overview safely can.

Where Zalfol Fits

Everything above describes a region where the condition is ordinary, the studies are patchy, the adults are the least counted of all, and the stigma keeps a lot of it off the books entirely. Zalfol can't fix the counting or change any country's regulations, and it doesn't claim to. What it can be is the support that's available today, in Arabic, with no waiting list — for the long stretch before an assessment, alongside one, or in the places this region's data shows the system simply hasn't reached yet.

• Feelings/QC — the Heart — is where a vague "something is off with how I focus" turns into a real, dated record you can bring to a clinician instead of trying to reconstruct it from memory in a short appointment. Feelings is not therapy. It is a log. No AI in this box, ever. Just an honest account of your own patterns, in your own hand.
• CEO Mode is planning structure for a brain that was never handed one that fit. It turns a month of vague intentions into a few clear objectives and the small steps underneath them, externalized so nothing has to be held in your head all at once — whether or not an assessment has happened yet.
• Dump is the relief valve for an overloaded mind on the days when everything is swirling at once. You empty it all out, unfiltered, and let the system help sort it afterward — often the simplest, most immediate thing that helps.
• Sponsoring puts another person on the record with you — someone who sees your check-ins and your progress. Being witnessed changes behavior in a way that willpower alone rarely does, and it costs nothing while you wait for, or navigate, a formal diagnosis.

None of this is a diagnosis, and none of it is a treatment. It doesn't replace a licensed clinician anywhere in the region, and it never will. What a cognitive system can do is hold the noticing, the planning, and the showing-up steady — in Arabic, on your worst days, without an appointment — for a region where the counting has barely begun and the adults have paid for it longest. Zalfol works with the wiring. Not against it.

Four countries, four different numbers, and not one of them adds up to a verdict on how common ADHD "really" is here. What they add up to is a region that is only just starting to look — country by country, study by study. The work ahead isn't inventing a single Arab-world statistic. It's exactly what these four reports have already begun: counting, one country at a time, what has always been there.

Frequently Asked Questions

Sources

1. Alhraiwil, N. J., Ali, A., Househ, M. S., Al-Shehri, A. M., & El-Metwally, A. A. (2015). Systematic review of the epidemiology of attention deficit hyperactivity disorder in Arab countries. Neurosciences (Riyadh), 20(2), 137–144. PMC4727626
2. Aboul-Ata, M. A., & Amin, F. A. (2018). The Prevalence of ADHD in Fayoum City (Egypt) Among School-Age Children: Depending on a DSM-5-Based Rating Scale. Journal of Attention Disorders, 22(2), 127–133. PMID 25814429
3. Younis, E. A., Shalaby, S. E. S., & Abdo, S. A. E. (2023). Screening of attention deficit hyperactivity disorder among preschool children, Gharbia Governorate, Egypt. BMC Psychiatry, 23, 285. PMC10126573
4. Farahat, T., Alkot, M., Rajab, A., & Anbar, R. (2014). Attention-Deficit Hyperactive Disorder among Primary School Children in Menoufia Governorate, Egypt. International Journal of Family Medicine, 2014, 257369. PMC4276697
5. Hamouda, M. M. (2025). Examining the effects of atomoxetine alone versus atomoxetine combined with risperidone in a sample of Egyptian children with ADHD. European Psychiatry, 68(S1). PMC12420061
6. Aljadani, A. H., Alshammari, T. S., Sadaqir, R. I., et al. (2023). Prevalence and Risk Factors of Attention Deficit-Hyperactivity Disorder in the Saudi Population: A Systematic Review and Meta-analysis. Saudi Journal of Medicine & Medical Sciences, 11(2), 126–134. Pooled prevalence 12.4% (95% CI 5.4–26%), 14 studies, N=455,334. PMC10211419
7. Al-Yateem, N., Rossiter, R. C., Al-Shujairi, A., Saifan, A. R., Radwan, H., Awad, M., Marzbani, M., Hijazi, H., & Slewa-Younan, S. (2023). Prevalence of Undiagnosed Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in the Young Adult Population of the United Arab Emirates: A National Cross-Sectional Study. Journal of Epidemiology and Global Health, 14(1), 45–53. PMC11043292
8. Al-Ghannami, S. S., Al-Adawi, S., Ghebremeskel, K., Cramer, M. T., Hussein, I. S., Min, Y., Jeyaseelan, L., Al-Sibani, N., Al-Shammakhi, S. M., Al-Mamari, F., & Dorvlo, A. S. S. (2018). Attention Deficit Hyperactivity Disorder and Parental Factors in School Children Aged Nine to Ten Years in Muscat, Oman. Oman Medical Journal, 33(3), 193–199. PMC5971059
9. Chan, M. F., Al Balushi, R., Al Falahi, M., Mahadevan, S., Al Saadoon, M., & Al-Adawi, S. (2021). Child and adolescent mental health disorders in the GCC: A systematic review and meta-analysis. International Journal of Pediatrics & Adolescent Medicine, 8(3), 134–145. PMC8319685
10. Balancing access to ADHD medication (editorial, 2023). BMC Medicine. Notes that psychostimulants used to treat ADHD are designated Schedule II controlled substances. PMC10280932
11. Faraone, S. V., et al. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. PMC8328933